Results 161 to 170 of about 1,141 (182)
Some of the next articles are maybe not open access.
Formulary Drug Review: Rezafungin
Hospital Pharmacy, 2023Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Brittney Kessel, Danial E. Baker
openaire +2 more sources
Rezafungin and invasive candida infections: a new game changing antifungal?
Lancet, The, 2023Jesus Guinea
exaly +3 more sources
Rezafungin: A Review in Invasive Candidiasis
DrugsRezafungin (Rezzayo®) is a next-generation echinocandin antifungal with improved pharmacokinetic properties over first-generation echinocandins that allows for once-weekly rather than once-daily intravenous administration. It has recently been approved for the treatment of adults with invasive candidiasis in the EU and UK, and is approved for adults ...
Simon Fung, Matt Shirley
openaire +2 more sources
Salvage therapy of complicated Candida albicans spondylodiscitis with Rezafungin
European Journal of Clinical Microbiology & Infectious DiseasesInvasive fungal infections, particularly those caused by Candida species, represent an increasing cause of hospital-related morbidity and mortality. Most commonly Candida spp. is the causative agent of candidemia and invasive candidiasis. In this report we present a complex case of Candida albicans spondylodiscitis, successfully treated with rezafungin,
Grasselli Kmet, Nina +5 more
openaire +3 more sources
Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix
Pharmacotherapy: The Journal of Human Pharmacology and Drug TherapyAbstractManagement of invasive fungal infections is challenging with growing antifungal resistance. Broad antifungal use has resulted in greater intrinsic and acquired resistance among Candida spp. It is important for clinicians to recognize the relationship between host susceptibility, site of infection, Candida resistance profiles, specific drug ...
Benjamin A. August +1 more
openaire +2 more sources
Rezafungin (Rezzayo) for Invasive Candida Infections
The Medical Letter on Drugs and TherapeuticsThe FDA has approved rezafungin (Rezzayo – Cidara/Melinta), an intravenous echinocandin antifungal, for once-weekly treatment of candidemia and invasive candidiasis (IC) in adults with limited or no alternative options. It is the first new drug to become available in the US in more than 15 years for treatment of systemic Candida infections.
openaire +2 more sources
Expert Opinion on Drug Metabolism and Toxicology
Rezafungin, formerly SP3025 and CD101, is a next-generation echinocandin, chemically related to anidulafungin, with differentiated pharmacokinetic characteristics, including a prolonged half-life allowing extended-interval dosing.Herein, we discuss the role of rezafungin in the treatment of candidemia and invasive candidiasis, with a specific focus on ...
Daniele Roberto Giacobbe
exaly +3 more sources
Rezafungin, formerly SP3025 and CD101, is a next-generation echinocandin, chemically related to anidulafungin, with differentiated pharmacokinetic characteristics, including a prolonged half-life allowing extended-interval dosing.Herein, we discuss the role of rezafungin in the treatment of candidemia and invasive candidiasis, with a specific focus on ...
Daniele Roberto Giacobbe
exaly +3 more sources
Early use of the novel antifungal rezafungin: a case series and literature review
Journal of Antimicrobial ChemotherapyAbstract Objectives Rezafungin is a novel echinocandin with a unique structural configuration enabling weekly IV dosing. We report on early use of rezafungin in our outpatient parenteral antibiotic therapy (OPAT) service, reviewing indications, treatment regimens, outcomes and adverse events in adult ...
H C Davidson +5 more
openaire +2 more sources